Novavax, Inc. (NVAX): Price and Financial Metrics
GET POWR RATINGS... FREE!
NVAX POWR Grades
- NVAX scores best on the Value dimension, with a Value rank ahead of 91.34% of US stocks.
- The strongest trend for NVAX is in Growth, which has been heading up over the past 179 days.
- NVAX's current lowest rank is in the Sentiment metric (where it is better than 0.69% of US stocks).
NVAX Stock Summary
- Novavax Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 2.81% of US listed stocks.
- Of note is the ratio of Novavax Inc's sales and general administrative expense to its total operating expenses; merely 4.02% of US stocks have a lower such ratio.
- Revenue growth over the past 12 months for Novavax Inc comes in at 141.02%, a number that bests 94.45% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Novavax Inc are ARDS, CKPT, RVMD, ZYME, and AUTL.
- NVAX's SEC filings can be seen here. And to visit Novavax Inc's official web site, go to www.novavax.com.
NVAX Valuation Summary
- In comparison to the median Healthcare stock, NVAX's price/earnings ratio is 151.23% lower, now standing at -18.7.
- NVAX's price/sales ratio has moved down 7.3 over the prior 243 months.
- NVAX's price/sales ratio has moved down 7.3 over the prior 243 months.
Below are key valuation metrics over time for NVAX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
NVAX | 2021-08-31 | 15.0 | 23.8 | -18.7 | -17.4 |
NVAX | 2021-08-30 | 14.7 | 23.3 | -18.3 | -17.0 |
NVAX | 2021-08-27 | 14.3 | 22.6 | -17.8 | -16.4 |
NVAX | 2021-08-26 | 14.5 | 23.0 | -18.1 | -16.7 |
NVAX | 2021-08-25 | 15.0 | 23.8 | -18.7 | -17.4 |
NVAX | 2021-08-24 | 14.7 | 23.3 | -18.3 | -16.9 |
NVAX Growth Metrics
- Its year over year net income to common stockholders growth rate is now at -433.31%.
- Its 5 year net cashflow from operations growth rate is now at 34.04%.
- Its year over year revenue growth rate is now at 4991.93%.

The table below shows NVAX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2021-12-31 | 1,146.29 | 322.946 | -1,743.751 |
2021-09-30 | 1,203.749 | 536.786 | -1,075.031 |
2021-06-30 | 1,181.929 | 672.432 | -949.91 |
2021-03-31 | 919.45 | 643.654 | -615.114 |
2020-12-31 | 475.598 | -42.541 | -418.259 |
2020-09-30 | 204.755 | 62.284 | -272.525 |
NVAX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NVAX has a Quality Grade of C, ranking ahead of 58.82% of graded US stocks.
- NVAX's asset turnover comes in at 0.6 -- ranking 60th of 680 Pharmaceutical Products stocks.
- GTHX, SRRA, and OPK are the stocks whose asset turnover ratios are most correlated with NVAX.
The table below shows NVAX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.600 | 1 | -14.595 |
2021-03-31 | 0.606 | 1 | -1.737 |
2020-12-31 | 0.502 | 1 | -0.781 |
2020-09-30 | 0.345 | 1 | -0.602 |
2020-06-30 | 0.126 | 1 | -0.222 |
2020-03-31 | 0.084 | 1 | -0.295 |
NVAX Price Target
For more insight on analysts targets of NVAX, see our NVAX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $264.20 | Average Broker Recommendation | 1.58 (Moderate Buy) |
NVAX Stock Price Chart Interactive Chart >
NVAX Price/Volume Stats
Current price | $55.29 | 52-week high | $277.80 |
Prev. close | $47.07 | 52-week low | $41.33 |
Day low | $46.19 | Volume | 7,476,200 |
Day high | $56.52 | Avg. volume | 5,134,910 |
50-day MA | $59.18 | Dividend yield | N/A |
200-day MA | $133.84 | Market Cap | 4.32B |
Novavax, Inc. (NVAX) Company Bio
Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.
Latest NVAX News From Around the Web
Below are the latest news stories about Novavax Inc that investors may wish to consider to help them evaluate NVAX as an investment opportunity.
4 Pharma Stocks to Buy Even if the Pandemic EndsHere are four pharma stocks that looks attractive for the long-term. |
Novavax Is a Buy on Recent Developments and Cheap ValuationNVAX stock is one of the major players in the vaccine market, which is one that is expected to grow substantially over the next few years. |
Why Novavax Stock Dived by Over 7% TodayNovavax (NASDAQ: NVAX) saw its shares wilt on Wednesday, due in no small part to a fairly deep price-target cut from an analyst. Mamtani's adjustment comes mere days before Novavax is slated to unveil its Q4 earnings. On Wednesday, Novavax announced that it has begun shipping the jab to the region. |
'We've all gone through hell': Serum Institute CEO on impact of COVID-19 around the worldThe CEO of the largest vaccine manufacturer in the world says that despite a slowdown in global vaccine uptake, he expects a strong Q2 and Q3. |
Is Novavax Stock A Buy As It Begins Shipping Covid Shots To Europe?Is Novavax stock a buy or a sell as it begins shipping its Covid vaccine to members of the European Union? Is NVAX stock a buy or sell? |
NVAX Price Returns
1-mo | 19.01% |
3-mo | -32.27% |
6-mo | -74.63% |
1-year | -63.32% |
3-year | 837.12% |
5-year | 179.24% |
YTD | -61.35% |
2021 | 28.30% |
2020 | 2,701.76% |
2019 | -89.18% |
2018 | 48.39% |
2017 | -1.59% |
Continue Researching NVAX
Want to see what other sources are saying about Novavax Inc's financials and stock price? Try the links below:Novavax Inc (NVAX) Stock Price | Nasdaq
Novavax Inc (NVAX) Stock Quote, History and News - Yahoo Finance
Novavax Inc (NVAX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...